TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03532867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Examination of pressures before stopping the exercise
Description: In healthy volunteers performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~* Macular and peri-papillary OCT in EDI mode (bilateral examination),~* Intraocular pressure (bilateral examination)~* Measurement of systolic and diastolic blood pressure~* Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Examination of pressure during the exercise
Description: In healthy volunteers performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~* Macular and peri-papillary OCT in EDI mode (bilateral examination),~* Intraocular pressure (bilateral examination)~* Measurement of systolic and diastolic blood pressure~* Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Examination of pressures after stopping the exercise
Description: In healthy patients performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~* Macular and peri-papillary OCT in EDI mode (bilateral examination),~* Intraocular pressure (bilateral examination)~* Measurement of systolic and diastolic blood pressure~* Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula.
Study: NCT03227120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation exercise
Description: Three times weekly exercise program of strengthening, balance and functional activities.~Weekly evaluation and progression with daily use of the Borg Rating of Perceived Exertion (RPE) supplemented with Heart Rate (HR) and Blood Pressure as needed to target the moderate intensity training level (40-60% HR Max) or above as appropriate to each individual.
Study: NCT01615536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Canine fossa trephine technique
Description: Patients undergoing standard ESS and a canine fossa trephine technique, which is a 6 mm puncture in the anterior wall of the maxillary sinus, to allow standard sinus debrider blades and instruments to pass into the sinus to clear polyps in the maxillary sinus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Endoscopic Sinus Surgery
Description: Patients undergoing standard ESS without canine fossa trephination with clearance of the maxillary sinus polyps via a wide maxillary antrostomy (WMA) with use of curved debrider surgical blades and instruments.
Study: NCT04282603

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss and Weight Maintenance
Description: Participants will consume a 1,200 kcal/day diet for twelve weeks. This is the amount of calories most commonly provided in medical weight loss programs, and considered the maximum allowable caloric intake to induce a physiologically significant weight loss. Following the weight loss portion of the trial, participants will enter the twelve week maintenance period, during which time they will consume one serving per day in place of lunch of the same meal replacement beverage used during medical weight loss.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Weight Loss and Weight Maintenance
Description: Participants will consume a 1,200 kcal/day diet for twelve weeks. This is the amount of calories most commonly provided in medical weight loss programs, and considered the maximum allowable caloric intake to induce a physiologically significant weight loss. Following the weight loss portion of the trial, participants will enter the twelve week maintenance period, during which time they will consume one serving per day in place of lunch of the same meal replacement beverage used during medical weight loss.
Study: NCT01175577

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chlorophyll complex, Standard Process
Description: One capsule, twice daily with meals for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Betatene, sold as Full Spectrum Carotenoid Complex
Description: One capsule per day with meals for 28 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Small carotenoid-rich meals
Description: Single carotenoid-enriched soup or salad serving eaten daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Safflower oil-filled capsules, one twice daily with meals
Study: NCT04583163

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler
Description: Transcranial Doppler is a non-invasive, painless, ultrasound technique that uses high frequency sound waves to measure the rate and direction of blood flow vessels in the brain.
Study: NCT01936870

Intervention type: DRUG
Intervention: Fesoterodine (Toviaz)
Description: Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.
Study: NCT04510818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Camrelizumab
Description: This is a single-arm study with all patients receiving these two drugs.
Study: NCT02459483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse phone call
Study: NCT03436082

Intervention type: DEVICE
Intervention: A mobile health platform
Description: Patients pilot testing the smartphone based, mobile health platform called HUGO. Patients will also be given syncable devices to use that will provide additional insights into their health and health outcomes.Patients will be queried about specific symptoms related to their procedure at enrollment, one week post-procedure, at 4 weeks and again at 8 weeks.

Intervention type: DEVICE
Intervention: A mobile health platform
Description: Patients pilot testing the smartphone based, mobile health platform called HUGO. Patients will also be given syncable devices to use that will provide additional insights into their health and health outcomes.Patients will be queried about specific symptoms related to their procedure at enrollment, one week post-procedure, at 4 weeks and again at 8 weeks.
Study: NCT00936923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: furosemide
Description: patients will take furosemide 60 or 120mg oral per day for 1 years .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: furosemide
Description: patients will take furosemide 60 or 120mg oral per day for 1 years .
Study: NCT03831906

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF Ultra (Ultra)
Description: The intervention will consist of the WHO standard of care for children with severe pneumonia plus the study intervention consisting in rapid detection of TB on the day of hospital admission using the Ultra assay performed on 1 NPA and 1 stool sample.~The sample flow will be organised to reduce time-to-results to 3 hours. Ultra will be performed at the hospital laboratory using a standard GeneXpert device, or implemented directly inward using a one-module, battery-operated GeneXpert device (G1 Edge).~Drugs will be available at the inpatient level to enable immediate initiation of TB treatment, as soon as a positive Ultra result is available.
Study: NCT00114517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17B-estradiol
Description: Oral 17B-estradiol 1 mg daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral 17B-estradiol placebo daily
Study: NCT01931319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous baclofen
Study: NCT03669341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Inspiration Breath Hold (DIBH)
Description: human-based DIBH method with short-term breath-hold training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Percussive Ventilation (HFPV)
Description: device-based HFPV technique
Study: NCT02178137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diacerien

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine/Chondroitin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01796366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 338 (GIPET I)
Description: Each subject will be allocated to one of three dosing periods only. The subject will receive oral insulin 338 and placebo, administered subcutaneously (s.c., under the skin) once daily for 10 days at fixed dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: S.c placebo administered in combination with insulin 338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Each subject will be allocated to one of three dosing periods only. The subject will receive insulin glargine for s.c. administration and oral placebo once daily for 10 days at fixed dose levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Oral placebo administered in combination with s.c. insulin glargine
Study: NCT04437134

Intervention type: OTHER
Intervention: On-line exercise and education
Description: Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. Patients are instructed in how to use alternative equipment at home for each exercise if necessary prior to the first on-line exercise session.~Education:~Patients attend two to three on-line educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment.

Intervention type: OTHER
Intervention: On-site exercise and education
Description: Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. The exercise sessions are delivered at physiotherapy clinics in Denmark.~Education:~Patients attend two to three on-site educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment.
Study: NCT02198404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sedation with propofol
Description: induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
Study: NCT04073979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mistral implantation
Description: Mistral implant is implanted in the Tricuspid valve
Study: NCT03416543

Intervention type: OTHER
Intervention: Puncture
Description: Puncture necessary for daily practice in patients with acute arthritis of RA or Gout or osteoarthritis
Study: NCT02495519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400 mg/day until disease progression
Study: NCT00774267

Intervention type: DRUG
Intervention: BZA 20 mg/CE 0.45 mg
Description: There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.

Intervention type: DRUG
Intervention: BZA 20 mg/CE 0.625 mg
Description: There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.

Intervention type: DRUG
Intervention: Raloxifene 60 mg
Description: There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as raloxifene tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.

Intervention type: DRUG
Intervention: Placebo
Description: There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as placebo capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
Study: NCT01006993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroFlo catheter
Description: NeuroFlo™ catheter 45 minute treatment
Study: NCT01528969

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: xylitol
Description: Subjects will chew 2 pieces of xylitol chewing gum (1,5 g/pellet) three times a day in the experimental group for a five-week period.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sorbitol
Description: Subjects will chew 2 pieces of sorbitol chewing gum (1,5 g/pellet) three times a day in the control group for a five-week period.
Study: NCT01908062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Naltrexone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As usual
Study: NCT00551278

Intervention type: DEVICE
Intervention: GeneSearch™ Breast Lymph Node (BLN) Assay
Description: For in vitro diagnostic use only.~The GeneSearch™ Breast Lymph Node (BLN) Assay is a qualitative, in vitro diagnostic test for the rapid detection of greater than 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes.~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Veridex lymph node cutting scheme, is required.
Study: NCT03057483

Intervention type: BIOLOGICAL
Intervention: Seasonal Influenza vaccine
Description: Seasonal Influenza vaccine

Intervention type: BIOLOGICAL
Intervention: Seasonal Influenza vaccine
Description: Seasonal Influenza vaccine

Intervention type: BIOLOGICAL
Intervention: Seasonal Influenza vaccine
Description: Seasonal Influenza vaccine

Intervention type: BIOLOGICAL
Intervention: Seasonal Influenza vaccine
Description: Seasonal Influenza vaccine

Intervention type: BIOLOGICAL
Intervention: Seasonal Influenza vaccine
Description: Seasonal Influenza vaccine
Study: NCT01993797

Intervention type: OTHER
Intervention: Lung US
Study: NCT05091775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol is used to treat and prevent mild to moderate acute fissure disease
Description: Comparison of two groups after 2 weeks in fissure wound healing, pain relief, pruritus, burning, bleeding, incontinence. Preliminary results of the study show the rate of fissure improvement 6 weeks after treatment, which is observed by clinical examination. Restoration is defined by complete epithelialization of the fissure site without scarring or residual cracks, and the secondary results will be a reduction in the amount of pain and other symptoms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Asacol is used to treat and prevent mild to moderate acute fissure disease
Description: Comparison of two groups after 2 weeks in fissure wound healing, pain relief, pruritus, burning, bleeding, incontinence. Preliminary results of the study show the rate of fissure improvement 6 weeks after treatment, which is observed by clinical examination. Restoration is defined by complete epithelialization of the fissure site without scarring or residual cracks, and the secondary results will be a reduction in the amount of pain and other symptoms.
Study: NCT02086500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1 gram of prehospital Tranexamic Acid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline control
Description: Saline Control
Study: NCT00643721

Intervention type: OTHER
Intervention: dehydration
Description: dehydration to 3% and 5% loss of total body water
Study: NCT00990197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal nicotine patch
Description: Subjects will apply the nicotine patch on the morning of their treatment day and will keep it on for 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal nicotine patch
Description: Subjects will apply the nicotine patch on the morning of their treatment day and will keep it on for 24 hours.
Study: NCT04803396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF2755A
Description: DF2755A was planned to be administered in two different parts:~Part A: Single oral dose administration on D1 according to the randomization (50, 150, 300 and 300 mg oad).~Part B: was planned (100 mg bid, 200 mg bid or 300 mg bid) but not performed (repeated oral administration from Day 1 to Day 14).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF2755A
Description: DF2755A was planned to be administered in two different parts:~Part A: Single oral dose administration on D1 according to the randomization (50, 150, 300 and 300 mg oad).~Part B: was planned (100 mg bid, 200 mg bid or 300 mg bid) but not performed (repeated oral administration from Day 1 to Day 14).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF2755A
Description: DF2755A was planned to be administered in two different parts:~Part A: Single oral dose administration on D1 according to the randomization (50, 150, 300 and 300 mg oad).~Part B: was planned (100 mg bid, 200 mg bid or 300 mg bid) but not performed (repeated oral administration from Day 1 to Day 14).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF2755A
Description: DF2755A was planned to be administered in two different parts:~Part A: Single oral dose administration on D1 according to the randomization (50, 150, 300 and 300 mg oad).~Part B: was planned (100 mg bid, 200 mg bid or 300 mg bid) but not performed (repeated oral administration from Day 1 to Day 14).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose administration on D1
Study: NCT04509219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Injection
Description: methylprednisolone pulse therapy, 30mg/kg, with maximal dose of 1000mg/day, for continue 3 days.
Study: NCT03071042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib Mesylate Tablets 425mg (500mg，675mg or 750mg) po. qd continuous;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60mg/m2 ivgtt day 1, q21d Combined use of Docetaxel and Apatinib
Study: NCT01847326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hyperfractionated radiation therapy
Description: Undergo hyperfractionated radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01416324

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Vehicle used to dilute the powder for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1 mg GSK2330672
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3 mg GSK2330672
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg GSK2330672
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg GSK2330672
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg GSK2330672
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg GSK2330672
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg GSK2330672
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Study: NCT03072108

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bonolive
Description: 2 caps per day of Bonolive

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 caps per day of Placebo
Study: NCT04655352

Intervention type: DIETARY_SUPPLEMENT
Intervention: Bacillus subtilis MB40
Description: 1-week placebo (maltodextrin and excipients) lead-in followed by 250 mg capsule (5 billion CFU/capsule) administered twice daily for 21 days